Para los que le interesen el sector farmaceutico del nasdaq
He visto este articulo sobre el top 10 de compañias con mas posibilidades de subir.
Algunas estan subiendo mucho hoy con mucho volumen tras tocar minimos.
Tienes que estar registrado para ver este contenido
Below are the top 10 Biotechnology stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
La Jolla Pharmaceutical Company (NASDAQ:
LJPC) has the 1st highest upside potential in this segment of the market. Its upside is 5900.0%. Its consensus target price is $6.30 based on the average of all estimates. Generex Biotechnology Corporation (NASDAQ:
GNBT) has the 2nd highest upside potential in this segment of the market. Its upside is 860.0%. Its consensus target price is $6.00 based on the average of all estimates. MiddleBrook Pharmaceuticals, Inc. (NASDAQ:
MBRK) has the 3rd highest upside potential in this segment of the market. Its upside is 581.8%. Its consensus target price is $3.00 based on the average of all estimates. ARYx Therapeutics, Inc. (NASDAQ:
ARYX) has the 4th highest upside potential in this segment of the market. Its upside is 448.8%. Its consensus target price is $6.75 based on the average of all estimates. Bionovo Inc. (NASDAQ:
BNVI) has the 5th highest upside potential in this segment of the market. Its upside is 331.0%. Its consensus target price is $2.50 based on the average of all estimates.
Cell Therapeutics, Inc. (NASDAQ:
CTIC) has the 6th highest upside potential in this segment of the market. Its upside is 328.5%. Its consensus target price is $2.87 based on the average of all estimates. Opexa Therapeutics Inc. (NASDAQ:
OPXA) has the 7th highest upside potential in this segment of the market. Its upside is 314.5%. Its consensus target price is $8.00 based on the average of all estimates. DUSA Pharmaceuticals, Inc. (NASDAQ:
DUSA) has the 8th highest upside potential in this segment of the market. Its upside is 305.4%. Its consensus target price is $6.00 based on the average of all estimates. Nile Therapeutics, Inc. (NASDAQ:
NLTX) has the 9th highest upside potential in this segment of the market. Its upside is 281.4%. Its consensus target price is $4.50 based on the average of all estimates. Encorium Group Inc. (NASDAQ:
ENCOD) has the 10th highest upside potential in this segment of the market. Its upside is 276.7%. Its consensus target price is $6.47 based on the average of all estimates.